ESMO Congress 2026Developing

atirmociclib

8 reports2 sourcesupdated 21 hours ago

Start here

No synthesis yet — start with the coverage timeline below.

Coverage timeline

Follow the coverage to see the different angles.

Oct 24

15:49
x.com
Very promising randomized results with the CDK4 selective inhibitor atirmociclib presented by @antgiorda. Next gen CDKs are here! #ESMO26 #ESMOAmbassadors
15:11
x.com
Results with $PFE's CDK4i atirmociclib at #ESMO26...in 2L breast cancer, a use that's no longer a focus (focus now on 1L). One treatment-related death with atirmo, from pneumonitis
15:10
x.com
Selective CDK4 inhibition in endocrine-resistant #BreastCancer: phase 2 results for atirmociclib + fulvestrant, an Oral Abstract Session at #ESMO26 @OncoAlert @Larvol
15:07
x.com
#FOURLIGHT1 CDK4 atirmociclib
15:06
x.com
Oral abstract #BreastCancer session at #ESMO26: phase 2 results with the #CDK4 inhibitor #atirmociclib in addition to #fulvestrant presented by the great @antgiorda 🇮🇹 in patients
15:06
x.com
FourLight shows 1st CDK4i Atirmociclib after CDK4/6i shows significant improvement in mPFS 9.4 vs 6.6 mos HR=0.60

Oct 23

21:40
x.com
Join Dr. Antonio Giordano (@antgiorda) at #ESMO26 for Proffered Paper Session 2, featuring data on the efficacy and safety of atirmociclib + fulvestrant in patients with HR+/HER2–
06:01
bydrug.pharmcube.com

Heat trend for this story

Heat now 38·Peak in the comparable set 68 (Oct 24 16:00)·Change over 24h in the comparable set +256%·Participants now 8

Participants counted8

Heat over time

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.